Funck, Jr. Robert E. 4
4 · ABBOTT LABORATORIES · Filed Feb 22, 2023
Insider Transaction Report
Form 4
Funck Robert E
Vice President, Controller
Transactions
- Award
Common shares without par value
2023-02-17+24,419→ 231,001 total - Award
Option (right to buy)
2023-02-17+96,301→ 96,301 totalExercise: $106.24From: 2024-02-17Exp: 2033-02-16→ Common Shares (96,301 underlying)
Holdings
- 10,000(indirect: By Trust)
Common shares without par value
- 500(indirect: By Daughter)
Common shares without par value
- 10,000(indirect: By Trust)
Common shares without par value
- 18,405(indirect: By Trust)
Common shares without par value
Footnotes (5)
- [F1]These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
- [F2]Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.
- [F3]Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2023.
- [F4]The reporting person disclaims beneficial ownership of all securities held by his daughter.
- [F5]Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,100 on February 17, 2024, 32,100 on February 17, 2025, and 32,101 on February 17, 2026.